Ex Vivo Lung Perfusion: A Review of Current and Future Application in Lung Transplantation
Tóm tắt
The number of waitlisted lung transplant candidates exceeds the availability of donor organs. Barriers to utilization of donor lungs include suboptimal lung allograft function, long ischemic times due to geographical distance between donor and recipient, and a wide array of other logistical and medical challenges. Ex vivo lung perfusion (EVLP) is a modality that allows donor lungs to be evaluated in a closed circuit outside of the body and extends lung donor assessment prior to final acceptance for transplantation. EVLP was first utilized successfully in 2001 in Lund, Sweden. Since its initial use, EVLP has facilitated hundreds of lung transplants that would not have otherwise happened. EVLP technology continues to evolve and improve, and currently there are multiple commercially available systems, and more under investigation worldwide. Although barriers to universal utilization of EVLP exist, the possibility for more widespread adaptation of this technology abounds. Not only does EVLP have diagnostic capabilities as an organ monitoring device but also the therapeutic potential to improve lung allograft quality when specific issues are encountered. Expanded treatment potential includes the use of immunomodulatory treatment to reduce primary graft dysfunction, as well as targeted antimicrobial therapy to treat infection. In this review, we will highlight the historical development, the current state of utilization/capability, and the future promise of this technology.
Tài liệu tham khảo
Smith S, Trivedi JR, Fox M, Van Berkel VH. Donor lung utilization for transplantation in the United States. J Heart Lung Transplant. 2020;39(4, Supplement):S374.
Reeb J, Keshavjee S, Cypel M. Expanding the lung donor pool: advancements and emerging pathways. Curr Opin Organ Transplant. 2015;20(5):498–505.
Canadian Institute for Health Information. Annual statistics on organ replacement in Canada: dialysis, transplantation and donation, 2008 to 2017. Canada. 2018.
Van Raemdonck D, Neyrinck A, Verleden GM, et al. Lung donor selection and management. Proc Am Thorac Soc. 2009;6(1):28–38.
Steen S, Liao Q, Wierup RPN, et al. Sjöberg Transplantation of lungs from non-heart-beating donors after functional assessment ex vivo. Ann Thorac Surg. 2003;76:244–52.
Nakajima D, Date H. Ex vivo lung perfusion in lung transplantation. Gen Thorac Cardiovasc Surg. 2021;69(4):625–30.
Schmack B, Weymann A, Mohite P, et al. Contemporary review of the organ care system in lung transplantation: potential advantages of a portable ex-vivo lung perfusion system. Expert Rev Med Devices. 2016;13(11):1035–41.
Schraufnagel DP, Steffen RJ, Vargo PR, et al. Devices for ex vivo heart and lung perfusion. Expert Rev Med Devices. 2018;15(3):183–91.
Warnecke G, Moradiellos J, Tudorache I, et al. Normothermic perfusion of donor lungs for preservation and assessment with the organ care system lung before bilateral transplantation: a pilot study of 12 patients. Lancet. 2012;380:1851–8.
Zhang ZL, van Suylen V, van Zanden JE, et al. First experience with ex vivo lung perfusion for initially discarded donor lungs in the Netherlands: a single-centre study. Eur J Cardiothorac Surg. 2018. https://doi.org/10.1093/ejcts/ezy373.
Cypel M, Yeung JC, Machuca T, et al. Experience with the first 50 ex vivo lung perfusions in clinical transplantation. J Thorac Cardiovasc Surg. 2012;144(5):1200–6.
Van Raemdonck D, Neyrinck A, Cypel M, et al. Ex vivo lung perfusion. Transplant Int. 2015;28:643–56.
Luo Q, Zhu L, Wang Y, et al. The conversional efficacy of ex vivo lung perfusion and clinical outcomes in patients undergoing transplantation of donor lungs by ex vivo lung perfusion: a meta-analysis. Ann Transplant. 2019;27(24):647–60.
Jirsch DW, Fisk RL, Couves CM. Ex vivo evaluation of stored lungs. Ann Thorac Surg. 1970;10(2):163–8.
Nelson K, Bobba C, Ghadiali S, et al. Animal models of ex vivo lung perfusion as a platform for transplantation research. World J Exp Med. 2014;4(2):7–15.
Kalka K, Keldenich Z, Carstens H, et al. Porcine slaughterhouse lungs for ex vivo lung perfusion—a pilot project. Am J Transl Res. 2020;12(10):6455–63.
Roman MA, Nair S, Tsui S, et al. Ex vivo lung perfusion: a comprehensive review of the development and exploration of future trends. Transplantation. 2013;96(6):509–18.
Steen S, Sjöberg T, Pierre L, et al. Transplantation of lungs from a non-heart-beating donor. Lancet. 2001;357(9259):825–9.
Wierup P, Haraldsson A, Nilsson F, et al. Ex vivo evaluation of nonacceptable donor lungs. Ann Thorac Surg. 2006;81(2):460–6.
Steen S, Ingemansson R, Eriksson L, et al. First human transplantation of a nonacceptable donor lung after reconditioning ex vivo. Ann Thorac Surg. 2007;83(6):2191–4.
Cypel M, Yeung JC, Hirayama S, et al. Technique for prolonged normothermic ex vivo lung perfusion. J Heart Lung Transplant. 2008;27(12):1319–25.
Cypel M, Yeung JC, Liu M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med. 2011;364(15):1431–40.
Possoz J, Neyrinck A, Van Raemdonck D. Ex vivo lung perfusion prior to transplantation: an overview of current clinical practice worldwide. J Thorac Dis. 2019;11(4):1635–50.
Briot R, Gennai S, Maignan M, et al. Ex vivo lung graft perfusion. Anaesth Crit Care Pain Med. 2016;35(2):123–31.
Warnecke G, Van Raemdonck D, Smith MA, et al. Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study. Lancet Respir Med. 2018;6(5):357–67.
Loor G, Warnecke G, Villavicencio MA, Smith MA, et al. Portable normothermic ex-vivo lung perfusion, ventilation, and functional assessment with the Organ Care System on donor lung use for transplantation from extended-criteria donors (EXPAND): a single-arm, pivotal trial. Lancet Respir Med. 2019;7(11):975–84.
Hsin M, Au T. Ex vivo lung perfusion: a potential platform for molecular diagnosis and ex vivo organ repair. J Thorac Dis. 2018;10(Suppl 16):S1871–83.
Aigner C, Klepetko W. Bilateral lung transplantation. Oper Tech Thorac Card Surg. 2012;17:181–93. https://doi.org/10.1053/j.optechstcvs.2012.09.001.
Chaney J, Suzuki Y, Cantu E 3rd, van Berkel V. Lung donor selection criteria. J Thorac Dis. 2014;6(8):1032–8.
Smits JM, van der Bij W, Van Raemdonck D, et al. Defining an extended criteria donor lung: an empirical approach based on the Eurotransplant experience. Transpl Int. 2011;24:393–400.
Lardinois D, Banysch M, Korom S, et al. Extended donor lungs: eleven years experience in a consecutive series. Eur J Cardiothorac Surg. 2005;27:762–7.
Snell GI, Levvey BJ, Levin K, et al. Donation after brain death versus donation after circulatory death: lung donor management issues. Semin Respir Crit Care Med. 2018;39(2):138–47.
Martens A, Van Raemdonck DE, Smits J, et al. A retrospective database analysis to evaluate the potential of ex vivo lung perfusion to recruit declined lung donors. Transpl Int. 2017;30(10):1002–10.
Gammie JS, Stukus DR, Pham SM, et al. Effect of ischemic time on survival in clinical lung transplantation. Ann Thorac Surg. 1999;68(6):2015–9 (discussion 2019–20).
Hsin MKY, Iskander I, Nakajima D, et al. Extension of donor lung preservation with hypothermic storage after normothermic ex vivo lung perfusion. J Heart Lung Transplant. 2016;35:130–6.
Okahara S, Levvey B, McDonald M, D’Costa R, Opdam H, Pilcher DV, Snell GI. A retrospective review of declined lung donors: estimating the potential of ex vivo lung perfusion. Ann Thorac Surg. 2021;112(2):443–9.
XVIVO Perfusion AB. XVIVO Perfusion System (XPSTM) with STEEN SolutionTM Professional Labeling. Göteborg, Sweden. 2019. https://www.accessdata.fda.gov/cdrh_docs/pdf18/P180014d.pdf
TransMedics, Inc. TransMedics® Organ Care System™ Clinical User Guide: OCS™ Lung System. Andover, MA. 2019. https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160013S002C.pdf
Sage AT, Richard-Greenblatt M, Zhong K, et al. Prediction of donor related lung injury in clinical lung transplantation using a validated ex vivo lung perfusion inflammation score. J Heart Lung Transplant. 2021;40(7):687–95.
Senior M. Beating the organ clock. Nat Biotechnol. 2018;36:488–92.
Murala JS, Whited WM, Banga A, et al. Ex vivo lung perfusion: how we do it. Indian J Thorac Cardiovasc Surg. 2021;1:1–12.
Cypel M, Yeung JC, Donahoe L, et al. Normothermic ex vivo lung perfusion: Does the indication impact organ utilization and patient outcomes after transplantation? J Thorac Cardiovasc Surg. 2019;S0022–5223(19):31732–5.
McMeekin N, Chrysos AE, Vale L, et al. Incorporating ex-vivo lung perfusion into the UK adult lung transplant service: an economic evaluation and decision analytic model. BMC Health Serv Res. 2019;19:326.
Hopkins PM, Chamber D, Smith I, et al. Cost effectiveness of ex vivo lung perfusion warrants analysis of long-term recipient outcome and donor organ utilization rate. JHLT. 2015;4:S174.
Fisher A, Andreasson A, Chrysos A, et al. An observational study of donor ex vivo lung perfusion in UK lung transplantation: DEVELOP-UK. Health Technol Assess. 2016;20(85):1–276.
Nilsson T, Wallinder A, Henriksen I, et al. Lung transplantation after ex vivo lung perfusion in two Scandinavian centres. Eur J Cardiothorac Surg. 2019;55(4):766–72.
Valenza F, Rosso L, Coppola S, et al. Ex vivo lung perfusion to improve donor lung function and increase the number of organs available for transplantation. Transpl Int. 2014;27(6):553–61.
Wey A, Valapour M, Skeans MA, et al. Heart and lung organ offer acceptance practices of transplant programs are associated with waitlist mortality and organ yield. Am J Transplant. 2018;18(8):2061–7.
Chancellor WZ, Charles EJ, Mehaffey JH, et al. Expanding the donor lung pool: how many donations after circulatory death organs are we missing? J Surg Res. 2018;223:58–63.
Palleschi AI, Rosso L, Ruggeri G, et al. Overcoming the limits of reconditioning: seventeen hours of EVLP with successful transplantation from uncontrolled circulatory death donor. Transplantation. 2021;105(12):2620–4.
Fitch ZW, Doberne J, Reynolds JM, et al. Expanding donor availability in lung transplantation: a case report of 5000 miles traveled. Am J Transplant. 2021;21(6):2269–72.
De Wolf J, Puyo P, Bonnette P, et al. Logistic ex vivo lung perfusion for hyperimmunized patients. Ann Thorac Surg. 2016;102(3):e205–6.
Based on Organ Procurement and Transplantation Network data as of 1/7/2022. OPTN.transplant.hrsa.gov/datarequest
Gilmour J, Griffiths C, Pither T, et al. Normothermic machine perfusion of donor-lungs ex-vivo: promoting clinical adoption. Curr Opin Organ Transplant. 2020;25(3):285–92.
Okamoto T, Niikawa H, Wheeler D, et al. Significance of lung weight in cellular ex vivo lung perfusion. J Surg Res. 2021;260:190–9.
Renne J, Gutberlet M, Voskrebenzev A, et al. Multiparametric MRI for organ quality assessment in a porcine Ex-vivo lung perfusion system. PLoS ONE. 2018;13(12): e0209103.
Ayyat KS, Okamoto T, Niikawa H, et al. A CLUE for better assessment of donor lungs: novel technique in clinical ex vivo lung perfusion. J Heart Lung Transplant. 2020; S1053–2498(20)31665-X
Iske J, Hinze CA, Salman J, et al. The potential of ex vivo lung perfusion on improving organ quality and ameliorating ischemia reperfusion injury. Am J Transplant. 2021;21(12):3831–9.
Caldarone L, Mariscal A, Sage A, et al. Neutrophil extracellular traps in ex vivo lung perfusion perfusate predict the clinical outcome of lung transplant recipients. Eur Respir J. 2019;53(4):1801736.
Kanou T, Nakahira K, Choi AM, et al. Cell-free DNA in human ex vivo lung perfusate as a potential biomarker to predict the risk of primary graft dysfunction in lung transplantation. J Thorac Cardiovasc Surg. 2020;S0022–5223(20):32354.
Bunsow E, Los-Arcos I, Martin-Gómez MT, Bello I, et al. Donor-derived bacterial infections in lung transplant recipients in the era of multidrug resistance. J Infect. 2020;80(2):190–6.
Snell G, Hiho S, Levvey B, et al. Consequences of donor-derived passengers (pathogens, cells, biological molecules and proteins) on clinical outcomes. J Heart Lung Transplant. 2019;38(9):902–6.
Tanaka S, Gauthier JM, et al. Bacterial products in donor airways prevent the induction of lung transplant tolerance. Am J Transplant. 2021;21(1):353–61.
Mehaffey JH, Charles EJ, Sharma AK, et al. Ex vivo lung perfusion rehabilitates sepsis-induced lung injury. Ann Thorac Surg. 2017;103(6):1723–9.
Nakajima D, Cypel M, Bonato R, et al. Ex vivo perfusion treatment of infection in human donor lungs. Am J Transplant. 2016;16(4):1229–37.
Zinne N, Krueger M, Hoeltig D, et al. Treatment of infected lungs by ex vivo perfusion with high dose antibiotics and autotransplantation: a pilot study in pigs. PLoS ONE. 2018;13(3): e0193168.
Michaelsen VS, et al. Safety of continuous 12-hour delivery of antimicrobial doses of inhaled nitric oxide during ex vivo lung perfusion. J Thorac Cardiovasc Surg. 2020. https://doi.org/10.1016/j.jtcvs.2020.11.150.
Galasso M, Feld JJ, Watanabe Y, et al. Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion. Nat Commun. 2019;10(1):481.
Lin H, Chen M, Tian F, Tikkanen J, et al. α1-Anti-trypsin improves function of porcine donor lungs during ex-vivo lung perfusion. J Heart Lung Transplant. 2018;37(5):656–66.
Ku TJY, et al. Ex-vivo delivery of monoclonal antibody (Rituximab) to treat human donor lungs prior to transplantation. EBioMedicine. 2020;60: 102994.
Ivulich S, Westall G, Dooley M, Snell G. The evolution of lung transplant immunosuppression. Drugs. 2018;78(10):965–82.
Hall DJ, Baz M, Daniels MJ, et al. Immediate postoperative inflammatory response predicts long-term outcome in lung-transplant recipients. Interact Cardiovasc Thorac Surg. 2012;15(4):603–7.
Haam S, Noda K, Philips BJ, et al. Cyclosporin A administration during ex vivo lung perfusion preserves lung grafts in rat transplant model. Transplantation. 2020;104(9):e252–9.
van Zanden JE, Leuvenink HGD, Verschuuren EAM, et al. Ex vivo perfusion with methylprednisolone attenuates brain death-induced lung injury in rats. Transplant Direct. 2021;7(4): e682.
Yeung JC, Wagnetz D, Cypel M, et al. Ex vivo adenoviral vector gene delivery results in decreased vector-associated inflammation pre- and post-lung transplantation in the pig. Mol Ther. 2012;20(6):1204–11.
Figueiredo C, Carvalho Oliveira M, Chen-Wacker C, et al. Immunoengineering of the vascular endothelium to silence MHC expression during normothermic ex vivo lung perfusion. Hum Gene Ther. 2019;30(4):485–96.
Brüggenwirth IMA, Martins PN. RNA interference therapeutics in organ transplantation: the dawn of a new era. Am J Transplant. 2020;20(4):931–41.